BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7707127)

  • 1. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
    Tallman MS; Hakimian D; Zanzig C; Hogan DK; Rademaker A; Rose E; Variakojis D
    J Clin Oncol; 1995 Apr; 13(4):983-8. PubMed ID: 7707127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.
    Juliusson G; Liliemark J
    J Clin Oncol; 1993 Apr; 11(4):679-89. PubMed ID: 8097528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
    Robak T; Boński JZ; Kasznicki M; Góra-Tybor J; Hellmann A; Konopka L; Dmoszyńska A; Dwilewicz-Trojaczek J; Wołowiec D;
    Eur J Haematol; 2002 Jul; 69(1):27-36. PubMed ID: 12270059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
    Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
    Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
    J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine in the treatment of chronic lymphocytic leukemia.
    Robak T
    Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
    Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
    Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
    Krykowski E; Warzocha K; Robak T
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
    Robak T; Błoński JZ; Kasznicki M
    Leuk Lymphoma; 2001 May; 41(5-6):545-57. PubMed ID: 11378572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
    Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dwilewicz-Trojaczek J; Stella-Hołowiecka B; Wołowiec D
    Hematol J; 2002; 3(5):244-50. PubMed ID: 12391542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
    Juliusson G; Liliemark J
    Ann Oncol; 1996 Apr; 7(4):373-9. PubMed ID: 8805929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
    Robak T; Błasinka-Morawiec M; Krykowski E; Kasznicki M; Płuzanska A; Potemski P; Hellmann A; Zaucha JM; Lewandowski K; Dmoszynska A; Hansz J; Komarnicki M; Konopka L; Durzynski T; Ceglarek B; Sikorska A; Kotlarek-Haus S; Mazur G; Urasinski I; Zdziarska B; Maj S; Kopec I; Skotnicki AB; Dwilewicz-Trojaczek J; Grieb P
    Leuk Lymphoma; 1996 Aug; 22(5-6):509-14. PubMed ID: 8882965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
    Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
    Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia.
    Juliusson G; Christiansen I; Hansen MM; Johnson S; Kimby E; Elmhorn-Rosenborg A; Liliemark J
    J Clin Oncol; 1996 Jul; 14(7):2160-6. PubMed ID: 8683250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
    Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
    Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).
    Betticher DC; Ratschiller D; Hsu Schmitz SF; von Rohr A; Hess U; Zulian G; Wernli M; Tichelli A; Tobler A; Fey MF; Cerny T
    Ann Oncol; 1998 Jul; 9(7):721-6. PubMed ID: 9739437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia.
    Robak T; Błasińska-Morawiec M; Błoński JZ; Dmoszyńska A
    Leuk Lymphoma; 1999 Jun; 34(1-2):151-7. PubMed ID: 10350343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.